PRPHOTCPharmaceutical PreparationsFiscal year ends December 31
ProPhase Labs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026
$0.01−0.00 (-6.16%)
Close on Oct 19, 2026
- Market cap
- $119.68K
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.9915 (−99.83%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
ProPhase Labs, Inc. saw revenue fall 31.2% to $3.85M over the twelve months to Jun 30, 2026. Free cash flow was -$8.34M.
Revenue
$3.85M
-31.2% vs. a year earlier
Operating income
-$15.56M
TTM Q2 2026
Free cash flow
-$8.34M
FY2025
EPS, diluted
-$1.74
FY2025
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $119.68K
- P/E ratio
- –
- Price to sales
- 0.03
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -6971.77%
Fundamentals
- Revenue
- $3.85M
- Net income
- -$22.46M
- EPS, diluted
- -$1.74
- Free cash flow
- -$8.34M
- Book value per share
- -$0.22
- Diluted shares
- 14M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$3.85M-31.2% YoY
Gross profit
$645.00K-51.3% YoY
Operating income
-$15.56M
Net income
-$22.46M
EPS, diluted
–
Free cash flow
–
Reported periodTrailing twelve months